Sanofi

ENXTPA:SAN Lagerbericht

Marktkapitalisierung: €93.4b

Sanofi Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Sanofi wird ein jährliches Gewinn- und Umsatzwachstum von 15.7% bzw. 4.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.6% betragen.

Wichtige Informationen

15.7%

Wachstumsrate der Gewinne

17.26%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum15.0%
Wachstumsrate der Einnahmen4.1%
Zukünftige Eigenkapitalrendite14.61%
Analystenabdeckung

Good

Zuletzt aktualisiert01 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

May 04
Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution

Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion

Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?

SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength

Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.

SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience

Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability

Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.

SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience

Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.

SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline

Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.

SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline

Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.

SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals

Sanofi's analyst price target has been modestly adjusted downward from $106.85 to $106.26. Analysts point to slight improvements in profit margin and future valuation metrics while maintaining a broadly stable outlook.

SAN: Forward Momentum Will Rely On Pipeline Success And Operational Execution

Sanofi's analyst price target saw a slight decrease to $106.85 from $106.90. Analysts cite moderating revenue growth expectations and a slightly higher discount rate impacting the updated valuation.

We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative

Oct 31
We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative

Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum

Sanofi's analyst price target has been slightly lowered from €108.31 to €106.90. Analysts cite modest improvements in revenue growth and profit margin, but note a more conservative outlook for the company's future valuation.

Pipeline Advances And Acquisitions Will Expand Therapeutic Horizons

Sanofi's slight decline in future P/E alongside an improved net profit margin suggests a modestly stronger earnings outlook, although this was not enough to materially shift the consensus analyst price target, which decreased fractionally from €109.22 to €108.31. What's in the News FDA approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) after insufficient response to previous treatment, based on positive Phase 3 results; also approved in UAE and under review in EU and China, with Fast Track and Orphan Drug designations for multiple indications.

Cautious Investors Not Rewarding Sanofi's (EPA:SAN) Performance Completely

Jul 27
Cautious Investors Not Rewarding Sanofi's (EPA:SAN) Performance Completely

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:SAN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202852,00510,19010,48413,8288
12/31/202749,5458,8459,28212,6339
12/31/202646,6888,1598,11012,7119
3/31/202647,3544,8296,80210,340N/A
12/31/202546,7164,9397,21210,750N/A
9/30/202545,9316,4307,92111,116N/A
6/30/202545,7386,3838,40311,214N/A
3/31/202545,1666,2187,89111,086N/A
12/31/202444,2865,4965,8869,081N/A
9/30/202448,4454,506N/AN/AN/A
6/30/202439,5473,6764,3378,117N/A
3/31/202446,2884,538N/AN/AN/A
12/31/202341,1095,0627,35210,258N/A
9/30/202345,6999,066N/AN/AN/A
6/30/202346,0458,6178,10710,264N/A
3/31/202346,1998,357N/AN/AN/A
12/31/202240,3047,9708,42310,526N/A
9/30/202244,3486,409N/AN/AN/A
6/30/202242,0396,6437,5949,620N/A
3/31/202240,3426,666N/AN/AN/A
12/31/202139,1756,2238,47910,522N/A
9/30/202138,4966,174N/AN/AN/A
6/30/202137,5465,7775,8278,219N/A
3/31/202136,93912,197N/AN/AN/A
12/31/202037,36912,2945,3357,418N/A
9/30/202037,65011,224N/AN/AN/A
6/30/202037,69211,1386,8348,491N/A
3/31/202038,2343,453N/AN/AN/A
12/31/201937,6312,855N/A7,715N/A
9/30/201936,9403,179N/AN/AN/A
6/30/201936,7633,591N/A6,953N/A
3/31/201936,2644,439N/AN/AN/A
12/31/201835,6774,319N/A5,547N/A
9/30/201835,3164,041N/AN/AN/A
6/30/201834,9853,243N/A6,596N/A
3/31/201835,4283,539N/AN/AN/A
12/31/201736,2213,773N/A7,379N/A
9/30/201736,4004,593N/AN/AN/A
6/30/201736,3154,744N/A8,133N/A
3/31/201735,6774,682N/AN/AN/A
12/31/201634,6964,395N/A7,838N/A
9/30/201634,3494,195N/AN/AN/A
6/30/201634,1154,154N/A8,122N/A
3/31/201634,5694,440N/AN/AN/A
12/31/201534,8614,411N/A8,920N/A
9/30/201537,2015,292N/AN/AN/A
6/30/201532,9104,628N/A8,561N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SANDas prognostizierte Gewinnwachstum (15.7% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: SANDie Erträge des Unternehmens (15.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (12.3% pro Jahr).

Hohe Wachstumserträge: SANDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: SANDie Einnahmen des Unternehmens (4.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.5% pro Jahr).

Hohe Wachstumseinnahmen: SANDie Einnahmen des Unternehmens (4.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SANDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.6%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/04 15:28
Aktienkurs zum Tagesende2026/05/04 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Sanofi wird von 53 Analysten beobachtet. 18 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research
null nullBanco de Sabadell. S.A.